药物信息为OXYCONTIN (OXYCODONE HCl CONTROLLED-RELEASE) TABLETS CII10 mg 15 mg 20 mg 30 mg 40 mg 60 mg* 80 mg* 160 mg* (Purdue Pharma LP): CLINICAL TRIALS
- WARNING:
- DESCRIPTION
- CLINICAL PHARMACOLOGY
- PHARMACOKINETICS AND METABOLISM
- Absorption
- Plasma Oxycodone by Time
- Food Effects
- Distribution
- Metabolism
- Excretion
- Pharmacodynamics
- CLINICAL TRIALS
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- DRUG ABUSE AND ADDICTION
- ADVERSE REACTIONS
- OVERDOSAGE
- SAFETY AND HANDLING
- HOW SUPPLIED
- CAUTION
- PATIENT INFORMATION
- 外部链接相关的OXYCONTIN (OXYCODONE HCl CONTROLLED-RELEASE) TABLETS CII10 mg 15 mg 20 mg 30 mg 40 mg 60 mg* 80 mg* 160 mg* (Purdue Pharma LP)
A double-blind placebo-controlled, fixed-dose, parallel group, two-week study was conducted in 133 patients with chronic, moderate to severe pain, who were judged as having inadequate pain control with their current therapy. In this study, 20 mg OxyContin q12h but not 10 mg OxyContin q12h decreased pain compared with placebo, and this difference was statistically significant.
- Drug Information Provided by National Library of Medicine (NLM).
这个站点被设计主要作为提示系统供合格的医师和其他医疗专家使用。 通过使用这个站点您了解并且接受DiagnosisPro.com不会使用作为一个诊断决策系统，并且不能使用做一个临床诊断或替换或者否决一位被准许的医疗保健专家的评断或临床诊断 (充分的使用条款). 我们遵循健康网络基金会的 医学和健康网站的行为准则. 点击这里核实
© 2013 MedTech USA, Inc. (最后更新在06/18/13)
